CAMBRIDGE, Mass. and BEIJING, China, May 14, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. BGNE HKEX: 06160))), a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that clinical and non-clinical data on BTK inhibitor BRUKINSA™ (zanubrutinib) and clinical data on anti-PD-1 antibody tislelizumab will be presented in an oral presentation and eight posters at the 25th European Hematology Association (EHA) Virtual Congress, taking place on June 11-14, 2020.
Oral Presentation:
| Title: | ASPEN: Results of a Phase 3 Randomized Trial Of Zanubrutinib Versus Ibrutinib for Patients with Waldenström Macroglobulinemia (WM) |
| Abstract #: | S225 |
| Session Title: | Indolent and Mantle-Cell Non-Hodgkin Lymphoma – Clinical |
| Presenter: | Meletios Dimopoulos, M.D., National and Kapodistrian University of Athens, Greece |
Poster Presentations:
| Title: | Updated Results of the ASPEN Trial from a Cohort of Patients with MYD88 Wild-Type Waldenström Macroglobulinemia |
| Abstract #: | EP1180 |
| Session Title: | Indolent and Mantle-Cell Non-Hodgkin Lymphoma – Clinical |
| Lead Author: | Meletios Dimopoulos, M.D., National and Kapodistrian University of Athens, Greece |
| Title: | Three-Year Follow-Up of Treatment-Naïve and Previously Treated Patients with Waldenström Macroglobulinemia (WM) Receiving Single Agent Zanubrutinib |
| Abstract #: | EP1168 |
| Session Title: | Indolent and Mantle-Cell Non-Hodgkin Lymphoma – Clinical |
| Lead Author: | Stephen Opat, MBBS, Monash University, Australia |
| Title: | Phase 1/2 Study of Single-Agent Zanubrutinib in Patients with Relapsed/Refractory Marginal Zone Lymphoma |
| Abstract #: | EP1165 |
| Session Title: | Indolent and Mantle-Cell Non-Hodgkin Lymphoma – Clinical |
| Lead Author: | Alessandra Tedeschi, M.D., Niguarda Cancer Center, Italy |
| Title: | Tislelizumab (BGB-A317) for Relapsed/Refractory Extranodal NK/T-Cell Lymphoma: Preliminary Efficacy and Safety Results from a Phase 2 Study |
| Abstract #: | EP1268 |
| Session Title: | Aggressive Non-Hodgkin Lymphoma – Clinical |
| Lead Author: | Huiqiang Huang, M.D., Ph.D., Sun Yat-sen University Cancer Center, China |
| Title: | Tislelizumab (BGB-A317) for Relapsed/Refractory Peripheral T-Cell Lymphomas: Safety and Efficacy Results from a Phase 2 Study |
| Abstract #: | EP1235 |
| Session Title: | Aggressive Non-Hodgkin Lymphoma – Clinical |
| Lead Author: | Pier Luigi Zinzani, M.D., Ph.D., University of Bologna, Italy |
| Title: | Biomarker Identification in Relapsed/Refractory Non-Germinal Center B-Cell–Like Diffuse Large B-Cell Lymphoma Treated with Zanubrutinib |
| Abstract #: | EP1246 |
| Session Title: | Aggressive Non-Hodgkin Lymphoma – Clinical |
| Lead Author: | Haiyan Yang, M.D., Zhejiang Cancer Hospital, China |
| Title: | Zanubrutinib (BGB-3111) in Combination with Rituximab in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma |
| Abstract #: | EP1271 |
| Session Title: | Aggressive Non-Hodgkin Lymphoma – Clinical |
| Lead Author: | Jianfeng Zhou, M.D., Tongji Medical College, China |
| Title: | Outcomes of Relapsed/Refractory MCL Patients Treated with Zanubrutinib Monotherapy in the Second Line and in Later Lines: A Pooled Analysis from 2 Studies |
| Abstract #: | EP1169 |
| Session Title: | Indolent and Mantle-Cell Non-Hodgkin Lymphoma – Clinical |
| Lead Author: | Keshu Zhou, M.D., Henan Cancer Hospital, China |
About BeiGene
BeiGene is a global, commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative medicines to improve treatment outcomes and access for patients worldwide. Our 3,800+ employees in China, the United States, Australia, and Europe are committed to expediting the development of a diverse pipeline of novel therapeutics for cancer. We currently market two internally-discovered oncology products: BTK inhibitor BRUKINSA™ (zanubrutinib) in the United States, and anti-PD-1 antibody tislelizumab in China. We also market or plan to market in China additional oncology products licensed from Amgen Inc., Celgene Logistics Sàrl, a Bristol Myers Squibb (BMS) company, and EUSA Pharma. To learn more about BeiGene, please visit www.beigene.com and follow us on Twitter at @BeiGeneUSA.
BeiGene Investor Contact
Craig West
+1 857-302-5189
ir@beigene.com
BeiGene Media Contact
Liza Heapes
+1 857-302-5663
media@beigene.com
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
